The Cancer Drugs Fund (CDF) in England emerged during the 2010 general election when the Conservative Party was keen to show that it would not deny patients new cancer drugs. It was intended as a temporary measure, pending the introduction of a new pricing model that would require the NHS to pay a price for a drug that reflected its ‘value’ rather than an amount set by the drug company.1,2 Value-based pricing never materialised and by March 2015, £968 million had been spent by the CDF on 74,380 patients.3 This included drugs that did not meet the National Institute for Health and Care Excellence's (NICE) adjusted cost-effectiveness …